AFFYMAX INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-08: Form 8-K; Period of report 2012-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-10-03: Form 8-K; Period of report 2012-10-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-08-08: Form 8-K; Period of report 2012-08-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-07-12: Form 8-K; Period of report 2012-07-12; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-08 | 8-K | 2012-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2012, Affymax, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2012. | a12-26541_18k.htm |
| 2012-10-03 | 8-K | 2012-10-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective October 1, 2012, Karin L. Walker, age 49, was appointed Vice President of Finance and Chief Accounting Officer of Affymax, Inc. (the “Company”). | a12-22627_18k.htm |
| 2012-08-08 | 8-K | 2012-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2012, Affymax, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2012. | a12-17915_18k.htm |
| 2012-07-12 | 8-K | 2012-07-12 | 8.01 Other Events | 8.01 On July 12, 2012, Takeda Pharmaceuticals U.S.A. and Affymax, Inc. announced that Takeda Pharmaceuticals America, Inc. had entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. | a12-16197_18k.htm |
| 2012-06-19 | 8-K | 2012-06-13 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. 5.02 On June 13, 2012, the Compensation Committee recommended, and the Board of Directors awarded, a product-approval bonus to Anne-Marie Duliege, M.D., M.S., the Company’s Chief Medical Officer, in recognition of her significant contributions in achieving first-cycle approval by the U.S. Food and Drug Administration of our first product, OMONTYS® (Peginesatide) Injection, on March 27, 2012. 5.07 On June 13, 2012, the Company held its Annual Meeting of Stockholders (the “Meeting”) at 4001 Miranda Avenue, Palo Alto, CA 94304. | a12-14920_18k.htm |
| 2012-05-07 | 8-K | 2012-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2012, Affymax, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2012. | a12-11158_18k.htm |
| 2012-04-27 | 8-K | 2012-04-24 | 8.01 Other Events | 8.01 On April 24, 2012, Affymax, Inc. and Takeda Pharmaceutical Company Limited announced that OMONTYS® (peginesatide) Injection is now available for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. | a12-10677_18k.htm |
| 2012-03-28 | 8-K | 2012-03-27 | 8.01 Other Events | 8.01 On March 27, 2012, Affymax, Inc. and Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. | a12-8258_18k.htm |
| 2012-03-27 | 8-K | 2012-03-26 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K that relates to the creation of a direct financial obligation of our company is incorporated by reference herein. 3.02 The information set forth above and referenced under Item 1.01 that relates to the issuance of the Warrants is hereby incorporated by reference into this Item 3.02. | a12-8100_18k.htm |
| 2012-03-14 | 8-K | 2012-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2012, Affymax, Inc. issued a press release announcing its financial results for the year ended December 31, 2011. | a12-7145_18k.htm |
| 2012-02-27 | 8-K | 2012-02-24 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On February 27, 2012, the Company announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize peginesatide. | a12-5900_18k.htm |
| 2012-02-02 | 8-K | 2012-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The bonus payouts are based on the individual performance of each executive as well as achievement against the corporate objectives. | a12-4123_18k.htm |